Growth factor treatment of demyelinating disease: At last, a leap into the light

Trends in Immunology

Volumn 23, Issue 11, 2002, Pages 512-516

  Ransohoff, Richard M ^a   Howe, Charles L ^b   Rodriguez, Moses ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH FACTOR; INTERLEUKIN 6; NEUROTROPHIC FACTOR;

ARTICLE; AUTOIMMUNE DISEASE; CELL DEATH; CELL SURVIVAL; DEMYELINATING DISEASE; ENCEPHALOMYELITIS; IMMUNITY; INFLAMMATION; MEDICAL RESEARCH; MULTIPLE SCLEROSIS; NERVE FIBER DEGENERATION; NERVE LESION; OLIGODENDROGLIA; PROTEIN FAMILY; PUBLICATION; REMYELINIZATION;

EID: 0036838576     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4906(02)02321-9     Document Type: Review

References (36)

1. Bjartmar C., Trapp B.D. Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. Curr. Opin. Neurol. 14:2001;271-278.
2. Linker R.A., et al. CNTF is a major protective factor in demyelinating CNS disease: a neurotrophic cytokine as modulator in neuroinflammation. Nat. Med. 8:2002;620-624.
3. Butzkueven H., et al. LIF receptor signaling limits immune-mediated demyelination by enhancing oligodendrocyte survival. Nat. Med. 8:2002;613-619.
4. Giess R., et al. Association of a null mutation in the CNTF gene with early onset of multiple sclerosis. Arch. Neurol. 59:2002;407-409.
5. Hickey W.F. The pathology of multiple sclerosis: a historical perspective. J. Neuroimmunol. 98:1999;37-44.
6. Prineas J.W., et al. Multiple sclerosis: remyelination of nascent lesions. Ann Neurol. 33:1993;137-151.
7. Chang A., et al. Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. N. Engl. J. Med. 346:2002;165-173.
8. Ludwin S.K. Understanding multiple sclerosis: lessons from pathology. Ann Neurol. 47:2000;691-693.
9. Lucchinetti C., et al. A quantitative analysis of oligodendrocytes in multiple sclerosis lesions. A study of 113 cases. Brain. 122:1999;2279-2295.
10. Lucchinetti C., et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 47:2000;707-717.
11. Rodriguez M., et al. Oligodendrocyte injury is an early event in lesions of multiple sclerosis. Mayo Clin. Proc. 68:1993;627-636.
12. Lassmann H., et al. Immunopathology of multiple sclerosis: report on an international meeting held at the Institute of Neurology of the University of Vienna. J. Neuroimmunol. 86:1998;213-217.
13. Miller R.H. Oligodendrocyte origins. Trends Neurosci. 19:1996;92-96.
14. Barres B.A., et al. Ciliary neurotrophic factor enhances the rate of oligodendrocyte generation. Mol. Cell. Neurosci. 8:1996;146-156.
15. Tsai H., et al. The chemokine receptor CXCR2 controls positioning of oligodendrocyte precursors in developing spinal cord by arresting their migration. Cell. 110:2002;373-383.
16. Park S.K., et al. Growth factor control of CNS myelination. Dev. Neurosci. 23:2001;327-337.
17. Marchionni M.A., et al. Neuregulin in neuron/glial interactions in the central nervous system. GGF2 diminishes autoimmune demyelination, promotes oligodendrocyte progenitor expansion, and enhances remyelination. Adv. Exp. Med. Biol. 468:1999;283-295.
18. Liu X., et al. Insulin-like growth factor I treatment reduces clinical deficits and lesion severity in acute demyelinating experimental autoimmune encephalomyelitis. Mult. Scler. 1:1995;2-9.
19. Liu X., et al. Insulin-like growth factor-I treatment reduces immune cell responses in acute non-demyelinative experimental autoimmune encephalomyelitis. J. Neurosci. Res. 47:1997;531-538.
20. Yao D.L., et al. Insulin-like growth factor-I given subcutaneously reduces clinical deficits, decreases lesion severity and upregulates synthesis of myelin proteins in experimental autoimmune encephalomyelitis. Life Sci. 58:1996;1301-1306.
21. Lovett-Racke A.E., et al. Regulation of experimental autoimmune encephalomyelitis with insulin-like growth factor (IGF-1) and IGF-1/IGF-binding protein-3 complex (IGF-1/IGFBP3). J. Clin. Invest. 101:1998;1797-1804.
22. Villoslada P., et al. Human nerve growth factor protects common marmosets against autoimmune encephalomyelitis by switching the balance of T helper cell type 1 and 2 cytokines within the central nervous system. J. Exp. Med. 191:2000;1799-1806.
23. Ransohoff R.M., Trebst C. Surprising pleiotropy of nerve growth factor in the treatment of experimental autoimmune encephalomyelitis. J. Exp. Med. 191:2000;1625-1630.
24. Rodriguez M., et al. Recombinant human IL-6 suppresses demyelination in a viral model of multiple sclerosis. J. Immunol. 153:1994;3811-3821.
25. Wolswijk G., Noble M. Identification of an adult-specific glial progenitor cell. Development. 105:1989;387-400.
26. Akassoglou K., et al. Oligodendrocyte apoptosis and primary demyelination induced by local TNF/p55TNF receptor signaling in the central nervous system of transgenic mice: models for multiple sclerosis with primary oligodendrogliopathy. Am. J. Pathol. 153:1998;801-813.
27. Louis J.C., et al. CNTF protection of oligodendrocytes against natural and tumor necrosis factor-induced death. Science. 259:1993;689-692.
28. Arnett H.A., et al. TNF α promotes proliferation of oligodendrocyte progenitors and remyelination. Nat. Neurosci. 4:2001;1116-1122.
29. Wiendl H., Hohlfeld R. Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. BioDrugs. 16:2002;183-200.
30. Sendtner M., et al. Cryptic physiological trophic support of motoneurons by LIF revealed by double gene targeting of CNTF and LIF. Curr. Biol. 6:1996;686-694.
31. Takahashi R., et al. A null mutation in the human CNTF gene is not causally related to neurological diseases. Nat. Genet. 7:1994;79-84.
32. Tofaris G.K., et al. Denervated Schwann cells attract macrophages by secretion of leukemia inhibitory factor (LIF) and monocyte chemoattractant protein-1 in a process regulated by interleukin-6 and LIF. J. Neurosci. 22:2002;6696-6703.
33. Guillet C., et al. Functionally active fusion protein of the novel composite cytokine CLC/soluble CNTF receptor. Eur. J. Biochem. 269:2002;1932-1941.
34. Marz P., et al. Neural activities of IL-6-type cytokines often depend on soluble cytokine receptors. Eur. J. Neurosci. 11:1999;2995-3004.
35. Murphy M., et al. Cytokines which signal through the LIF receptor and their actions in the nervous system. Prog. Neurobiol. 52:1997;355-378.
36. Senaldi G., et al. Novel neurotrophin-1/B cell-stimulating factor-3: a cytokine of the IL-6 family. Proc. Natl. Acad. Sci. U. S. A. 96:1999;11458-11463.